Published in Drug Law Weekly, June 2nd, 2009
"Consequently, numerous novel non-TZD compounds were synthesized and antidiabetic efficacy was evaluated to identify PPAR gamma agonists for potential clinical use. On the other hand, many studies have documented that the antitumor activity of PPAR gamma agonists is PPAR gamma independent. Here we...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.